Genetically determined telomere length and multiple myeloma risk and outcome.


Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
14 04 2021
Historique:
received: 07 09 2020
accepted: 11 03 2021
revised: 01 03 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 6 1 2022
Statut: epublish

Résumé

Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design (retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that, combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk. This approach has been already successfully attempted in various cancer types but never in MM. We tested the "teloscore" in 2407 MM patients and 1741 controls from the International Multiple Myeloma rESEarch (IMMeNSE) consortium. We observed an increased risk for longer genetically determined telomere length (gdTL) (OR = 1.69; 95% CI 1.36-2.11; P = 2.97 × 10

Identifiants

pubmed: 33854038
doi: 10.1038/s41408-021-00462-y
pii: 10.1038/s41408-021-00462-y
pmc: PMC8046773
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74

Références

Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Blood Cancer J. 2020 Sep 1;10(8):89
pubmed: 32873778
Genes (Basel). 2018 Apr 24;9(5):
pubmed: 29695106
Nat Genet. 2011 Nov 27;44(1):58-61
pubmed: 22120009
JAMA Oncol. 2017 May 1;3(5):636-651
pubmed: 28241208
Hum Mol Genet. 2012 Dec 15;21(24):5385-94
pubmed: 23001564
Int J Oncol. 2012 Mar;40(3):625-38
pubmed: 22159523
Nat Genet. 2013 Apr;45(4):422-7, 427e1-2
pubmed: 23535734
PLoS One. 2011;6(6):e20466
pubmed: 21695195
Neuropsychopharmacology. 2019 Mar;44(4):757-765
pubmed: 30559463
Exp Hematol. 2010 Oct;38(10):854-9
pubmed: 20600576
Int J Cancer. 2015 Mar 1;136(5):E351-8
pubmed: 25066524
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9293-8
pubmed: 20421499
Nat Genet. 2013 Oct;45(10):1221-1225
pubmed: 23955597
Int J Cancer. 2014 Dec 15;135(12):2910-7
pubmed: 24771230
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Eur J Haematol. 2012 Jan;88(1):8-30
pubmed: 21883480
Br J Haematol. 2016 Sep;174(6):991-3
pubmed: 26568154
Nat Rev Genet. 2005 Aug;6(8):611-22
pubmed: 16136653
Leukemia. 2012 Jun;26(6):1419-22
pubmed: 22182917
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1238-50
pubmed: 21467229
Cancer Causes Control. 2016 Oct;27(10):1219-28
pubmed: 27581250
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
Br J Haematol. 2012 May;157(3):331-8
pubmed: 22590720
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Br J Haematol. 2018 Nov;183(3):375-384
pubmed: 30079960
Front Med. 2016 Jun;10(2):191-203
pubmed: 27185042
Cancer. 1975 Sep;36(3):842-54
pubmed: 1182674
Carcinogenesis. 2016 Jun;37(6):576-582
pubmed: 27207662
Int J Cancer. 2019 Mar 15;144(6):1275-1283
pubmed: 30325019
Nat Commun. 2016 Jan 08;7:10290
pubmed: 26743840
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2447-54
pubmed: 25103821
Hum Mol Genet. 2015 Sep 15;24(18):5356-66
pubmed: 26138067
Br J Haematol. 2017 Jul;178(1):94-98
pubmed: 28342200
Int J Epidemiol. 2016 Dec 1;45(6):1961-1974
pubmed: 27616674
Hum Genet. 2015 Jul;134(7):679-89
pubmed: 25986438
Leuk Lymphoma. 2019 Jul;60(7):1803-1811
pubmed: 30633655
Hum Mol Genet. 2016 Apr 15;25(8):1663-76
pubmed: 27008888
Oncotarget. 2016 Sep 13;7(37):59029-59048
pubmed: 27437873
Nat Genet. 2013 May;45(5):522-525
pubmed: 23502783
J Natl Cancer Inst. 2014 Sep 17;106(10):
pubmed: 25231748
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Eur Urol. 2017 Nov;72(5):747-754
pubmed: 28797570
Nat Commun. 2015 Jul 22;6:7539
pubmed: 26198393
J Natl Cancer Inst. 2013 Apr 3;105(7):459-68
pubmed: 23468462
Neuro Oncol. 2014 Apr;16(4):505-12
pubmed: 24366909
Br J Haematol. 2012 Sep;158(6):805-9
pubmed: 22823248
Science. 2009 Nov 13;326(5955):948-52
pubmed: 19965504
Eur Heart J. 2008 Nov;29(21):2689-94
pubmed: 18762552
Breast Cancer Res. 2018 Apr 17;20(1):29
pubmed: 29665866
Oncotarget. 2015 Dec 15;6(40):42468-77
pubmed: 26646793
Pediatr Res. 2020 May;87(6):1060-1065
pubmed: 31783399

Auteurs

Matteo Giaccherini (M)

Department of Biology, University of Pisa, Pisa, Italy.

Angelica Macauda (A)

Department of Biology, University of Pisa, Pisa, Italy.
Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Enrico Orciuolo (E)

Haematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Marcin Rymko (M)

Department of Hematology, Copernicus Hospital, Torun, Poland.

Karolina Gruenpeter (K)

Department of Haematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.

Charles Dumontet (C)

Hospices Civils de Lyon, Lyon, France.

Malgorzata Raźny (M)

Department of Hematology, Rydygier Specialistic Hospital, Cracow, Poland.

Victor Moreno (V)

Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, CIBERESP and Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Gabriele Buda (G)

Haematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Katia Beider (K)

Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Judit Varkonyi (J)

Semmelweis University, Budapest, Hungary.

Hervé Avet-Loiseau (H)

Laboratory for Genomics in Myeloma, Institut Universitaire du Cancer and University Hospital, Centre de Recherche en Cancerologie de Toulouse, Toulouse, France.

Joaquín Martinez-Lopez (J)

Hospital 12 de Octubre, Complentese University, CNIO, CIBERONC, Madrid, Spain.

Herlander Marques (H)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal and ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Marzena Watek (M)

Department of Hematology, Holy Cross Cancer Center, Kielce, Poland.
Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Maria Eugenia Sarasquete (ME)

Hematology Department, University Hospital of Salamanca, CIBERONC, Salamanca, Spain.

Vibeke Andersen (V)

Department of Biochemistry, University Hospital of Southern Jutland, Sønderborg, Denmark.
IRS-Center Soenderjylland, University Hospital of Southern Jutland, Aabenraa, Denmark.

Lionel Karlin (L)

Hospices Civils de Lyon, Lyon, France.

Anna Suska (A)

Department of Hematology, Jagiellonian University Medical College, Krakow, Poland.

Marcin Kruszewski (M)

Department of Hematology, University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland.

Niels Abildgaard (N)

Department of Hematology, Odense University Hospital, Odense, Denmark.

Marek Dudziński (M)

Department of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.

Aleksandra Butrym (A)

Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.

Arnold Nagler (A)

Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Annette Juul Vangsted (AJ)

Department of Hematology, Rigshospitalet, Copenhagen, Denmark.

Katalin Kadar (K)

Semmelweis University, Budapest, Hungary.

Tomczak Waldemar (T)

Department of Haemato-oncology and Bone Marrow Transplantation and Department of Internal Medicine in Nursing, Medical University of Lublin, Lublin, Poland.

Krzysztof Jamroziak (K)

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Svend Erik Hove Jacobsen (SEH)

Department of Biochemistry, University Hospital of Southern Jutland, Sønderborg, Denmark.

Lene Hyldahl Ebbesen (LH)

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.

Michał Taszner (M)

Department of Hematology and Transplantology Medical University of Gdansk, Gdańsk, Poland.

Grzegorz Mazur (G)

Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.

Fabienne Lesueur (F)

Inserm, U900, Institut Curie, PSL University, Mines ParisTech, Paris, France.

Matteo Pelosini (M)

U.O. Dipartimento di Ematologia, Azienda USL Toscana Nord Ovest, Livorno, Italy, currently Ospedale Santa Chiara, Pisa, Italy.

Ramon Garcia-Sanz (R)

Hematology Department, University Hospital of Salamanca, CIBERONC, Salamanca, Spain.

Artur Jurczyszyn (A)

Department of Hematology, Jagiellonian University Medical College, Krakow, Poland.

Delphine Demangel (D)

Hospices Civils de Lyon, Lyon, France.

Rui Manuel Reis (RM)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal and ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.

Elżbieta Iskierka-Jażdżewska (E)

Department of Hematology, Medical University of Lodz, Łódź, Poland.

Miroslaw Markiewicz (M)

Department of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.

Federica Gemignani (F)

Department of Biology, University of Pisa, Pisa, Italy.

Edyta Subocz (E)

Department of Hematology, Military Institute of Medicine, Warsaw, Poland.

Daria Zawirska (D)

Department of Haematology, University Hospital in Cracow, Cracow, Poland.

Agnieszka Druzd-Sitek (A)

Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Anna Stępień (A)

Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łódź, Poland.

M Henar Alonso (MH)

Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, CIBERESP and Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Juan Sainz (J)

Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.

Federico Canzian (F)

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. f.canzian@dkfz.de.

Daniele Campa (D)

Department of Biology, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH